Effects of calcitonin in metastatic bone carcinoma, osteoporosis, polyostotic fibrous dysplasia and hypercalcemia.
D000230:Adenocarcinoma; D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D001859:Bone Neoplasms / Q000378:metabolism*; D002116:Calcitonin / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D002118:Calcium / Q000097:blood / Q000652:urine; D002675:Child, Preschool; D003687:Dehydroepiandrosterone / Q000494:pharmacology; D005260:Female; D005357:Fibrous Dysplasia of Bone / Q000378:metabolism*; D006801:Humans; D006909:Hydroxyproline / Q000097:blood; D006934:Hypercalcemia / Q000378:metabolism*; D007273:Injections, Intramuscular; D008274:Magnesium / Q000097:blood / Q000652:urine; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010024:Osteoporosis / Q000378:metabolism*
D003687:Dehydroepiandrosterone; D002116:Calcitonin; D000469:Alkaline Phosphatase; D008274:Magnesium; D006909:Hydroxyproline; D002118:Calcium